Status:
UNKNOWN
Study to Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia
Lead Sponsor:
Ahn-Gook Pharmaceuticals Co.,Ltd
Conditions:
Primary Hypercholesterolemia
Eligibility:
All Genders
19-79 years
Phase:
PHASE3
Brief Summary
To Evaluate the Efficacy and Safety of Combination Therapy of AGT and AGZ Versus Monotherapy of AGT in Patients With Primary Hypercholesterolemia.
Detailed Description
A Multi-center, Randomized, Double-blinded, Active-controlled, Factorial Design Phase 3 Clinical Trial
Eligibility Criteria
Inclusion
- Patients with primary hypercholesterolemia
Exclusion
- The subject not meet the specified LDL-C level
Key Trial Info
Start Date :
December 8 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 8 2022
Estimated Enrollment :
264 Patients enrolled
Trial Details
Trial ID
NCT05206578
Start Date
December 8 2020
End Date
September 8 2022
Last Update
January 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yonsei severance Hospital
Seoul, South Korea